research highlights in this issue: hematology/oncology ... · hematology/oncology (aspho), asco...
TRANSCRIPT
Summer 2013
In This Issue:
American Association
for Cancer Research
(AACR), American
Society of Clinical
Oncology (ASCO),
American Society of
Pediatric
Hematology/Oncology
(ASPHO), ASCO
Gastrointestinal &
Genitourinary Cancers
Symposia, International
Conference on
Malignant Lymphoma,
Society of Gynecologic
Oncologists (SGO), and
Others
Cooperative Group
Abstracts:
Breast Cancer
CNS Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Head and Neck Cancer
Leukemia,
Myelodysplasia, and
Transplantation
Lung Cancer
Lymphoma and
Plasma Cell Disorders
Melanoma/Skin Cancers
Sarcoma/Bone and
Soft Tissue Cancers
Other Cancer
NCI Abstracts:
DCTD/DCP Abstracts
The Clinical Trials Cooperative Group Program, sponsored by the National Cancer Institute (NCI), is designed to promote and support clinical trials of new cancer treatments, cancer control and prevention strategies, quality-of-life issues during and after interventions, as well as cancer imaging trials that target therapy, surveillance, and biomarkers of therapeutic responses. An issue of this report will be distributed biannually in Summer (post AMI, AACR, ASCO, SGO, and SNM) and in Winter (post ASCO Breast Symposium, ASH, ACRIN, ASTRO, ISOQOL, RSNA, SABCS and AMI/SMI joint meeting) to highlight the research presentations of the Cooperative Groups and the supporting activities of NCI investigators from the Division of Cancer Treatment and Diagnosis - Cancer Therapy Evaluation Program, Cancer Diagnosis Program, Cancer Imaging Program and Radiation Research Program, and from the Division of Cancer Prevention.
Research Highlights in this Issue:
GOG-0240: This phase III trial involved a 2x2 randomization of two chemotherapy arms,
paclitaxel/carboplatin vs. paclitaxel/topotecan with a secondary randomization to
bevacizumab. In 2012, the DSMB review determined non-superiority of the platinum-free
arm and the study continued until the 2013 analysis for the effect of the addition of
bevacizumab (given 15 mg/kg with chemotherapy every 3 weeks until progression of
disease). Chemotherapy + bevacizumab was superior in overall survival (OS), 17 v. 13.3
months (HR 0.71, CI 0.54-0.94; p=0.0035), and progression-free survival (PFS), 8.2 v 5.9
months (HR 0.67, CI 0.54-0.82; p=0.0002). This is the first randomized phase III study in
recurrent cervical cancer to yield an OS advantage. SAEs were increased in the
bevacizumab arm as expected for bevacizumab toxicity (thromboembolism, GI/GU
fistula); quality of life was lower, but this did not reach significance.
RTOG-0825: RTOG-0825 evaluated if addition of bevacizumab to standard
chemoradiation (CRT) improved overall survival (OS) or progression-free survival (PFS)
in newly diagnosed glioblastoma multiforme (GBM). 637 patients were randomized to the
standard CRT + placebo or standard CRT + bevacizumab. At progression, patients were
allowed to crossover or continue bevacizumab. Secondary analyses evaluated impact of
MGMT methylation and prognostic 9-gene signature status. No difference was found
between arms for OS (median 16.1 vs. 15.7 months, p = 0.11). PFS was extended for the
CRT + bevacizumab arm (7.3 vs. 10.7 months, p = 0.004). Patients with MGMT
methylation had superior OS (23.2 vs. 14.3 mo, p < 0.001) and PFS (14.1 vs. 8.2 mo, p <
0.001), but neither the 9-gene signature nor MGMT methylation predicted selective benefit
for bevacizumab treatment.
NCI-Sponsored Groups Meetings Report 2 of 26
Summer 2013
Cooperative Group Abstracts
Breast Cancer
ACOSOG/Alliance
Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch A, Flippo-Morton
TS, Byrd DR, Ollila DW, Julian TB, McLaughlin SA, Hunt K: Factors affecting sentinel lymph node
identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG
Z1071. Annals of Surgical Oncology 2013; 20(1 suppl): S8-S9; Abst. 9. http://expo.jspargo.com/exhibitor/web/SSOAbstracts.pdf
Other Participant(s) in the Trial: CALGB/Alliance, NCCTG/Alliance, NSABP, SWOG Protocol(s): ACOSOG-Z1071
Buzdar A, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig GW, Royce M,
Hunt K: ACOSOG Z1041 (Alliance): Definitive analysis of randomized neoadjuvant trial comparing
FEC followed by paclitaxel plus trastuzumab (FEC -> P+T) with paclitaxel plus trastuzumab followed
by FEC plus trastuzumab (P+T -> FEC+T) in HER2+ operable breast cancer. J Clin Oncol 2013; 31(15
suppl): Abst. 502. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/502
Protocol(s): ACOSOG-Z1041 CALGB/Alliance
Carey LA, Berry DA, Ollila D, Harris L, Krop IE, Weckstein D, Henry NL, Anders CK, Cirrincione
CT, Winer EP, Perou CM, Hudis CA: Clinical and translational results of CALGB 40601: A
neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-
positive breast cancer. J Clin Oncol 2013; 31(15 suppl): Abst. 500. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/500?sid=211d90d6-54e6-40ec-951b-49deb5d6be8c
Other Participant(s) in the Trial: SWOG Protocol(s): CALGB-40601
Lichtman SM, Cirrincione C, Hurria A, Jatoi A, Theodoulou M, Wolff AC, Gralow JR, Morganstern
DE, Magrinat GC, Cohen HJ, Muss HB: Effect of renal function (RF) on outcomes in the adjuvant
treatment of older women with breast cancer (>65 years): CALGB/CTSU 49907 (CC) ancillary data
study. J Clin Oncol 2013; 31(15 suppl): Abst. 9515. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/9515?sid=fea596f0-002c-4023-b07b-229ba9d8b056
Other Participant(s) in the Trial: ECOG, NCCTG/Alliance, NCIC Clinical Trials Group, SWOG Protocol(s): CALGB-49907
Ligibel JA, Cirricione C, Liu M, Citron M, Ingle J, Gradishar W, Martino S, Sikov WM, Michaelson
RA, Hudis C, Winer E, Barry W: Body mass index (BMI), tumor subtype, and relapse-free survival
(RFS) in CALGB 9741 (Alliance). J Clin Oncol 2013; 31(15 suppl): Abst. 1032. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/1032?sid=c5d6e4ba-d61c-4dcd-ae36-d5717fe928f4
Other Participant(s) in the Trial: ECOG, NCCTG/Alliance, SWOG Protocol(s): C9741
NCI-Sponsored Groups Meetings Report 3 of 26
Summer 2013
Ollila D, Berry D, Cirrincione C, Carey L, Amos K, Henry NL, Winer E, Hudis C, Golshan M: Impact
of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from
CALGB 40601 (Alliance). J Clin Oncol 2013; 31(15 suppl): Abst. 501. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/501?sid=211d90d6-54e6-40ec-951b-49deb5d6be8c
Other Participant(s) in the Trial: SWOG Protocol(s): CALGB-40601
Polite BN, Allred JB, Rugo HS, Cipriano T, Cirrincione C, Gehlert SJ, Paskett ED, Hudis C, Winer
EP: Differences in psychosocial factors among diverse women enrolled in a phase III Cooperative
Group metastatic breast cancer trial (CALGB 40502/Alliance). J Clin Oncol 2013; 31(15 suppl): Abst.
9581. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/9581?sid=985b67e7-cc5b-40f4-bf45-2f2c35cfb9f0
Other Participant(s) in the Trial: ECOG, NCCTG/Alliance Protocol(s): CALGB-40502
Shulman L, Berry D, Cirrincione C, Becker H, Perez E, O’Regan R, Martino S, Shapiro CL, Atkin sJ,
Schneider C, Kimmick G, Burstein H, Norton L, Muss H, Hudis C, Winer E: Comparison of
doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for
breast cancer in women with 0-3 positive axillary nodes: CALGB 40101. J Clin Oncol 2013; 31(15
suppl): Abst. 1007. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/1007?sid=9be34414-e040-4be0-b71e-0184942113f8
Other Participant(s) in the Trial: ECOG, NCCTG/Alliance, SWOG Protocol(s): CALGB-40101 ECOG
Partridge AH, Sepucha K, O'Neill A, Miller KD, Baker E, Dang CT, Northfelt DW, Sledge GW,
Schneider BP: Does biomarker information impact patients’ preferences for therapy? J Clin Oncol
2013; 31(15 suppl): Abst. 6527. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/6527?sid=13e98c79-02fd-4a5d-80f5-dd9411395629
Other Participant(s) in the Trial: CALGB/Alliance, NCCTG/Alliance Protocol(s): E5103
Ruddy KJ, O'Neill A, Miller KD, Schneider BP, Baker E, Sparano JA, Dang CT, Northfelt DW,
Sledge GW: Biomarker prediction of chemotherapy-related amenorrhea. J Clin Oncol 2013; 31(15
suppl): Abst. 9508. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/9508?sid=50f97193-0ab7-4c5b-ac14-3cdfb8756fe5
Other Participant(s) in the Trial: CALGB/Alliance, NCCTG/Alliance Protocol(s): E5103 Sanford S, Zhao F, Salsman J, Chang VT, Wagner LI, Fisch MJ: Symptom burden among young
adults with breast or colorectal cancer ECOG (E2Z02). Ann Behav Med 2013; 45(2 suppl): s58; Abst.
03A 2015. http://link.springer.com/content/pdf/10.1007%2Fs12160-013-9469-7.pdf
Protocol(s): E2Z02
NCI-Sponsored Groups Meetings Report 4 of 26
Summer 2013
NCCTG/Alliance
Clynes R, Knutson KL, Ballman K, Erskine CL, Norton N, Sumrall SV, Northfelt D, Tan W, Calfa C,
Pegram M, Perez EA: Combination trastuzumab and chemotherapy to induce immunity to multiple
tumor antigens in patients with HER2-positive metastatic breast cancer: NCCTG (Alliance) studies
N0337 and N98-32-52. J Clin Oncol 2013; 31(15 suppl): Abst. 521. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/521?sid=9c0743c8-049a-44b6-9683-a12b8751e413
Protocol(s): N0337, N98-32-52
Knutson KL, Perez EA, Ballman K, Erskine CL, Fox N, McCarl C-A, Norton N, Sumrall SV,
Northfelt D, Tan W, Calfa C, Pegram M, Clynes R: Generation of adaptive HER2-specific immunity
in HER2 breast cancer patients by addition of trastuzumab to chemotherapy in the adjuvant setting:
NCCTG (Alliance) study N9831. J Clin Oncol 2013; 31(15 suppl): Abst. 522. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/522?sid=dff5d48c-9847-4e9b-aa1b-e941e2cae2b1
Protocol(s): NCCTG N9831
Moreno-Aspitia A, Liu H, Hillman D, Rowland KM, Geiger X, Stella PJ, Kourlas P, Gross HM, Karlin
N, Bury MJ, Soori GS, Nassar A, Perez EA: N0937(Alliance): Final clinical results and correlative
data from the phase II trial of cisplatin (C) and the novel agent brostallicin (B) in patients with
metastatic triple-negative breast cancer (mTNBC). J Clin Oncol 2013; 31(15 suppl): Abst. 1059. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/1059?sid=9044e9d9-b4d1-450b-97da-56d952dba654
Protocol(s): N0937
Perez EA, Butler SM, Dueck AC, Baehner FL, Jamshidian F, Cherbavaz DB, Thompson EA, Shak S,
Kaufman PA, Davidson NE, Gralow J, Asmann YW, Ballman KV: The relationship between
quantitative HER2 gene expression by the 21-gene RT-PCR assay and adjuvant trastuzumab (H)
benefit in NCCTG (Alliance) N9831. J Clin Oncol 2013; 31(15 suppl): Abst. 520. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/520?sid=a3c2c841-adcd-4c75-b1e3-209b4696957b
Other Participant(s) in the Trial: CALGB/Alliance, ECOG, NCIC Clinical Trials Group, SWOG Protocol(s): NCCTG N9831 NCIC Clinical Trials Group
Chapman J-AW, Shepherd LE, Ingle JN, Muss HB, Pritchard KI, Gelmon KA, Whelan TJ, Elliott C,
Goss PE: Competing risks of death in NCIC CTG MA.27 adjuvant exemestane versus anastrozole. J
Clin Oncol 2013; 31(15 suppl): Abst. 564. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/564?sid=65a010bf-9414-4eff-bfe8-11b70d1bd7e4
Other Participant(s) in the Trial: CALGB/Alliance, ECOG, NCCTG/Alliance, SWOG Protocol(s): NCIC-MA.27
Goodwin PJ, Parulekar W, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, Rastogi P, Mayer
IA, Hobday TJ, Lemieux J, Thompson AM, Pritchard KI, Whelan TJ, Mukherjee SD, Chalchal HI, Oja
CD, Tonkin KS, Bernstein V, Chen BE, Stambolic V: Effect of metformin versus placebo on weight
and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant
randomized controlled trial in early-stage breast cancer (BC). J Clin Oncol 2013; 31(15 suppl): Abst.
1033. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/1033?sid=04c03831-a2e2-42af-91b0-299ec82d688a
Other Participant(s) in the Trial: CALGB/Alliance, ECOG, NCCTG/Alliance, NSABP, SWOG Protocol(s): NCIC-MA.32
NCI-Sponsored Groups Meetings Report 5 of 26
Summer 2013
NSABP
Cobleigh MA, Anderson SJ, Julian TB, Siziopikou KP, Arthur DW, Rabinovitch R, Zheng P,
Mamounas EP, Wolmark N: NSABP B-43: A phase III clinical trial to compare trastuzumab (T) given
concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by
lumpectomy (Lx). J Clin Oncol 2013; 31(15 suppl): Abst. TPS666. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/TPS666?sid=1b1638f1-75c0-4ee2-a01a-d0e14a84e3b6
Other Participant(s) in the Trial: CALGB/Alliance, ECOG, NCCTG/Alliance, RTOG, SWOG Protocol(s): NSABP-B-43
Fehrenbacher L, Jeong J-H, Rastogi P, Geyer CE, Paik S, Ganz PA, Land SR, Costantino JP, Swain
SM, Mamounas EP, Wolmark N: NSABP B-47: A randomized phase III trial of adjuvant therapy
comparing chemotherapy alone to chemotherapy plus trastuzumab in women with node-positive or
high-risk node-negative HER2-low invasive breast cancer. J Clin Oncol 2013; 31(15 suppl): Abst.
TPS1139. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/TPS1139?sid=dda96f3c-1392-45e1-8f3d-49b265f85539
Other Participant(s) in the Trial: ECOG, RTOG, SWOG Protocol(s): NSABP-B-47
Julian TB, Anderson SJ, Krag DN, Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mamounas
EP, Wolmark N: 10-yr follow up results of NSABP B-32, a randomized phase III clinical trial to
compare sentinel node resection to conventional axillary dissection in clinically node-negative breast
cancer patients. J Clin Oncol 2013; 31(15 suppl): Abst. 1000. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/1000?sid=c01c5256-b53f-468e-9340-9e6d81a131e2
Protocol(s): NSABP-B-32
Mamounas EP, Tang G, Paik S, Baehner FL, Liu Q, Jeong J-H, Kim S-R, Butler SM, Jamshidian F,
Cherbavaz DB, Sing AP, Shak S, Julian TB, Lembersky BC, Wickerham DL, Costantino JP, Wolmark
N: The 21-gene Recurrence Score predicts risk of locoregional recurrence in node (+), ER (+) breast
cancer after adjuvant chemotherapy and tamoxifen: Results from NSABP B-28. Annals of Surgical
Oncology 2013; 20(1 suppl): S6; Abst. 2. http://expo.jspargo.com/exhibitor/web/SSOAbstracts.pdf
Protocol(s): NSABP-B-28 SWOG
Budd GT, Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn KJ,
Albain KS, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BA, Flaherty LE, Livingston
RB, Lew D, Gralow JR, Hortobagyi GN: S0221: Comparison of two schedules of paclitaxel as
adjuvant therapy for breast cancer. J Clin Oncol 2013; 31(15 suppl): Abst. CRA1008. http://meeting.ascopubs.org/cgi/content/abstract/31/18_suppl/CRA1008?sid=835ff275-1d05-470f-a0d7-4b1b9f3267c2
Other Participant(s) in the Trial: CALGB/Alliance, ECOG, NCCTG/Alliance, NCIC Clinical Trials Group Protocol(s): S0221
NCI-Sponsored Groups Meetings Report 6 of 26
Summer 2013
Chavez-MacGregor M, Barlow WE, Gonzalez-Angulo AM, Rastogi P, Mamounas EP, Ganz PA,
Schott A, Paik S, Lew D, Bandos H, Hortobagyi GN: Phase III randomized, placebo-controlled clinical
trial evaluating the use of adjuvant endocrine therapy with or without one year of everolimus in
patients with high-risk, hormone receptor- (HR) positive and HER2-neu-negative breast cancer:
SWOG/NSABP S1207. J Clin Oncol 2013; 31(15 suppl): Abst. TPS657. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/TPS657?sid=ecc4f723-290c-4442-bf25-8832e4ffd792
Other Participant(s) in the Trial: NSABP Protocol(s): S1207
CNS Cancer
NCCTG/Alliance
Galanis E, Sarkaria J, Anderson K, Wu W, Jaeckle K, Giannini C, Buckner J, Wen P: Phase I/II trial of
vorinostat combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed
glioblastoma (GBM) (N0874-ABTC0902, Alliance): Final results of the phase I trial. J Clin Oncol
2013; 31(15 suppl): Abst. 2046. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/2046?sid=c613b886-1b1c-45b2-a5cd-091e308c56b1
Other Participant(s) in the Trial: ACOSOG/Alliance, CALGB/Alliance Protocol(s): N0874
Jaeckle K, Schiff D, Anderson S, Galanis E, Stella P, Flynn P, Sarkaria J, Giannini C, Erickson B,
Buckner J: NCCTG (Alliance) N0572: A phase II trial of sorafenib and temsirolimus in recurrent
glioblastoma (GBM) patients who progress following prior RT/temozolomide (TMZ) and VEGF
inhibitors (VEGFi). J Clin Oncol 2013; 31(15 suppl): Abst. 2014. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/2014?sid=165fe81a-424a-4104-aacf-b90d52c885c2
Protocol(s): N0572
Massett H, Jaeckle KA, Dilts DM, Denicoff A, Souhan E, Hopkins JR, Mann BS: Rapid online
feedback to improve clinical trial accrual: CODEL anaplastic glioma (AG) (NCCTG/Alliance N0577)
as a model. J Clin Oncol 2013; 31(15 suppl): Abst. 1596. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/1596?sid=b80465e4-a247-4a22-a915-7a427bb84709
Protocol(s): N0577
RTOG
Armstrong TS, Won M, Wefel JS, Gilbert MR, Pugh SL, Brachman D, Komaki R, Crocker IR, Robins
HI, Lee RJ, Mehta MP, Wendland MM: Comparative Impact of Treatment on Patient Reported
Outcomes (PROs) in Patients with Glioblastoma (GBM) Enrolled in RTOG 0825. J Clin Oncol 2013;
31(15 suppl): Abst. 2003. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/2003?sid=1e3a5449-e458-45f7-85c9-6fd094fc9e71
Other Participant(s) in the Trial: ECOG, NCCTG/Alliance Protocol(s): RTOG-0825
Chinnaiyan P, Won M, Wen PY, Rojiani A, Wendland MM, DiPetrillo TA, Corn BW, Mehta MP:
RTOG 0913: A Phase I Study of Daily Everolimus (RAD001) in Combination with Radiation Therapy
and Temozolomide in Patients with Newly Diagnosed Glioblastoma. J Clin Oncol 2013; 31(15 suppl):
Abst. 2047. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/2047?sid=36a70aea-e4d6-48c1-b4a0-9e04f31780ee
Protocol(s): RTOG 0913
NCI-Sponsored Groups Meetings Report 7 of 26
Summer 2013
Fisher BJ, Lui J, Macdonald DR, Lesser GJ, Coons S, Brachman D, Ryu S, Werner-Wasik M, Bahary
JP, Hu C, Mehta MP: A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for
High Risk Low-Grade Gliomas: Preliminary Results of RTOG 0424. J Clin Oncol 2013; 31(15 suppl):
Abst. 2008. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/2008?sid=201ec576-05fb-4896-b30f-97416cf699e5
Protocol(s): RTOG-0424
Gilbert MR, Dignam J, Won M, Blumenthal DT, Vogelbaum MA, Aldape KD, Colman H, Chakravarti
A, Jeraj R, Armstrong TS, Wefel JS, Brown PD, Jaeckle KA, Schiff D, Atkins JN, Brachman D,
Werner-Wasik M, Komaki R, Sulman EP, Mehta MP: RTOG 0825: Phase III Double-blind Placebo-
controlled Trial Evaluating Bevacizumab (Bev) in Patients (Pts) with Newly Diagnosed Glioblastoma
(GBM). J Clin Oncol 2013; 31(15 suppl): Abst. 1. http://meeting.ascopubs.org/cgi/content/abstract/31/18_suppl/1?sid=d1ab9092-14cb-4024-94e2-ccd82885e424
Other Participant(s) in the Trial: ECOG, NCCTG/Alliance Protocol(s): RTOG-0825
Glass J, Won M, Schultz CJ, Brat D, Bartlett N, Suh JH, Fisher BJ, Liepman MK, Mehta MP: Pre-
Irradiation Chemotherapy with Methotrexate, Rituximab, and Temozolomide and Post-Irradiation
Temozolomide for Primary Central Nervous System Lymphoma: RTOG 0227 Phase II Study Results.
J Clin Oncol 2013; 31(15 suppl): Abst. 2033. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/2033?sid=6d834dea-b6a3-49f3-90ee-52d296c190e5
Protocol(s): RTOG-0227
Sulman EP, Won M, Blumenthal DT, Vogelbaum MA, Colman H, Jenkins RB, Chakravarti A, Jeraj R,
Brown PD, Jaeckle KA, Schiff D, Dignam J, Atkins JN, Brachman D, Werner-Wasik M, Komaki R,
Gilbert MR, Mehta MP, Aldape KD: Molecular Predictors of Outcome and Response to Bevacizumab
(BEV) based on Analysis of RTOG 0825, a Phase III Trial Comparing Chemoradiation (CRT) with
and without Bev in Patients with Newly Diagnosed Glioblastoma (GBM). J Clin Oncol 2013; 31(15
suppl): Abst. LBA2010. http://meeting.ascopubs.org/cgi/content/abstract/31/18_suppl/LBA2010?sid=d1415c23-5af0-428a-97d7-3b325eb06c7f
Other Participant(s) in the Trial: ECOG, NCCTG/Alliance Protocol(s): RTOG-0825
Wefel JS, Pugh SL, Armstrong TS, Gilbert MR, Won M, Wendland MM, Brachman D, Komaki R,
Crocker IR, Robins HI, Lee RJ, Mehta MP: Neurocognitive Function (NCF) Outcomes in Patients with
Glioblastoma (GBM) Enrolled in RTOG 0825. J Clin Oncol 2013; 31(15 suppl): Abst. 2004. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/2004?sid=21deb172-24a5-4900-9971-2c686b279728
Other Participant(s) in the Trial: ECOG, NCCTG/Alliance Protocol(s): RTOG-0825
Gastrointestinal Cancer
CALGB/Alliance
Hurwitz H, Cushman S, Jiang C, Shterev I, Mahoney MR, Niedzwiecki D, Mayer RJ, Venook AP,
Owzar K, Nixon AB: Tumor markers of efficacy and resistance to cetuximab (C) treatment in
metastatic colorectal cancer (mCRC): Results from CALGB 80203 (Alliance). J Clin Oncol 2013;
31(15 suppl): Abst. 11011. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/11011?sid=8da84e74-5d65-4c40-a3e7-7ac4b4d622c3
Protocol(s): CALGB-80203
NCI-Sponsored Groups Meetings Report 8 of 26
Summer 2013
Naughton MJ, Schrag D, Venook AP, Niedzwiecki D, Anderson RT, Lenz H-J, Grubbs SS: Quality of
life (QOL) and toxicity among patients in CALGB 80405. J Clin Oncol 2013; 31(15 suppl): Abst.
3611. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/3611?sid=c1634dd9-82ab-4bf4-bb6f-25af47e651ec
Other Participant(s) in the Trial: ECOG, NCCTG/Alliance, SWOG Protocol(s): CALGB-80405
Van Loon K, Owzar K, Jiang C, Kindler HL, Mulcahy MF, Niedzwiecki D, O'Reilly EM, Fuchs CS,
Innocenti F, Venook AP: 25-hydroxyvitamin D levels and survival in patients with advanced
pancreatic cancer (APC): Findings from CALGB 80303. J Clin Oncol 2013; 31(15 suppl): Abst. 4022. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/4022?sid=161285f4-9060-4f67-bdd3-4c85b2762aa0
Other Participant(s) in the Trial: ECOG Protocol(s): CALGB-80303 ECOG
Nimeiri HS, Feng Y, Catalano P, Meropol NJ, Giantonio BJ, Sigurdson ER, Martenson JA, Whitehead
RP, Sinicrope FA, Mayer RJ, O’Dwyer PJ, Benson AB: Intergroup randomized phase III study of
postoperative irinotecan, 5-fluorouracil, and leucovorin versus oxaliplatin, 5-fluorouracil, and
leucovorin versus 5-fluorouracil and leucovorin for patients with stage II or III rectal cancer receiving
either preoperative radiation and 5-fluorouracil or postoperative radiation and 5-fluorouracil: ECOG
E3201 - An updated survival analysis. J Clin Oncol 2013; 31(15 suppl): Abst. E14711. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/e14711?sid=beab91bf-3391-436b-bc83-23d368fbeb68
Other Participant(s) in the Trial: CALGB/Alliance, NCCTG/Alliance, NSABP, SWOG Protocol(s): E3201 Sanford S, Zhao F, Salsman J, Chang VT, Wagner LI, Fisch MJ: Symptom burden among young
adults with breast or colorectal cancer ECOG (E2Z02). Ann Behav Med 2013; 45(2 suppl): s58; Abst.
03A 2015. http://link.springer.com/content/pdf/10.1007%2Fs12160-013-9469-7.pdf
Protocol(s): E2Z02 NCCTG/Alliance
Alberts S, Soori G, Shi Q, Wigle D, Sticca R, Miller R, Leenstra J, Peller P, Wu T, Yoon H,
Drevyanko T, Ko S, Mattar B, Nikcevich D, Behrens R, Khalil M, Kim G: Randomized phase II trial
of extended versus standard neoadjuvant therapy for esophageal cancer, NCCTG (Alliance) trial
N0849. J Clin Oncol 2013; 31(15 suppl): Abst. 4026. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/4026?sid=e5c77e6a-a960-4e50-8bfb-c294c1516fdd
Protocol(s): N0849
Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Stella PJ, Atherton P, Seisler D, Qamar R, Lewis GC,
Grothey A: Phase III randomized, placebo (PL)-controlled, double-blind study of intravenous
calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT), N08CB: An
Alliance for Clinical Trials in Oncology study. J Clin Oncol 2013; 31(15 suppl): Abst. 3501. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/3501?sid=afb15112-3f62-4e22-9fb1-e2c23f83070c
Protocol(s): N08CB
NCI-Sponsored Groups Meetings Report 9 of 26
Summer 2013
Lee A, Shi Q, Pavey E, Sargent DJ, Alberts SR, Sinicrope FA, Berenberg J, Goldberg R, Diasio RB:
Validation of DPYD variants DPYD*2A, I560S, and D949V as predictors of 5-fluorouracil (5-FU)-
related toxicity in stage III colon cancer (CC) patients from adjuvant trial NCCTG N0147. J Clin
Oncol 2013; 31(15 suppl): Abst. 3510. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/3510?sid=2f408d27-7862-4e30-bca6-bee561220776
Other Participant(s) in the Trial: CALGB/Alliance, ECOG, NSABP, SWOG Protocol(s): N0147
Smyrk TC, Tougeron D, Thibodeau SN, Singh S, Muranyi A, Shanmugam K, Grogan TM, Alberts SR,
Shi Q, Sinicrope FA: Detection of the BRAFV600E protein in human colon carcinomas by a mutation-
specific antibody. J Clin Oncol 2013; 31(15 suppl): Abst. 3576. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/3576?sid=f0134e5f-25a7-4733-a399-655c35115963
Other Participant(s) in the Trial: CALGB/Alliance, ECOG, NSABP, SWOG Protocol(s): N0147 NSABP
McCahill LE, Yothers G, Sharif S, Petrelli NJ, Lopa SH, O'Connell MJ, Wolmark N: A phase II trial
of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab for
patients with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor:
Updated results of NSABP C-10 with definitive survival analysis. J Clin Oncol 2013; 31(4 suppl):
Abst. 468. http://meeting.ascopubs.org/cgi/content/abstract/31/4_suppl/468?sid=f8ae2a0d-c5c5-41c6-8b08-b79bf6945e41
Protocol(s): NSABP-C-10
Renfro LA, Grothey A, Saltz L, André T, Labianca R, Alberts SR, Loprinzi CL, Yothers G, Sargent
DJ: Accent-based nomograms (NGs) to predict time to recurrence (TTR) and overall survival (OS) in
stage III colon cancer (CC). J Clin Oncol 2013; 31(15 suppl): Abst. 3618. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/3618?sid=4ec5d27b-719d-47c3-9be4-9ed9bdc0ec53
Other Participant(s) in the Trial: NCCTG/Alliance Protocol(s): NSABP-C-04, NSABP-C-05, NSABP-C-06, NSABP-C-07 RTOG
Lawrence YR, Moughan J, Magliocco A, Klimowicz A, Regine WF, Mowat RB, DiPetrillo TA, Small
W, Winter K, Guha C, Crane C, Dicker AP: Elevated expression of mismatch repair enzyme MLH1 is
associated with prolonged overall survival in resected pancreatic cancer treated with adjuvant
chemoradiation, a biomarker analysis of RTOG 9704. American Association for Cancer Research
(AACR), Washington, DC, Apr 2013. Abst. 3553. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3086&sKey=100cd1c8-60e0-47d6-8d0e-b53fff787821&cKey=04e08ca1-de40-4649-8f37-0ccf7e033790&mKey=%7b9B2D28E7-24A0-466F-A3C9-07C21F6E9BC9%7d
Other Participant(s) in the Trial: ECOG, SWOG Protocol(s): RTOG-9704
Swisher S, Moughan J, Komaki R, Ajani JA, Wu T, Hofstetter WL, Konski A, Willett C: Final results
of RTOG 0246: A Phase II study of selective surgical resection for locoregionally advanced
esophageal cancer treated with a paclitaxel based chemoradiation regimen. J Clin Oncol 2013; 31(4
suppl): Abst. 7. http://meeting.ascopubs.org/cgi/content/abstract/31/4_suppl/7?sid=15035411-001b-4d43-bca7-2796759f1940
Protocol(s): RTOG-0246
NCI-Sponsored Groups Meetings Report 10 of 26
Summer 2013
SWOG
Chung V, McDonough S, Philip PA, Backlund Cardin D, Lowy AM, Benedetti JK, Blanke CD:
SWOG S1115: Randomized phase II clinical trial of selumetinib (AZD6244; ARRY 142886) hydrogen
sulfate (NSC-748727) and MK-2206 (NSC-749607) versus mFOLFOX in patients with metastatic
pancreatic cancer after prior chemotherapy. J Clin Oncol 2013; 31(15 suppl): Abst. TPS4145. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/TPS4145?sid=4f0d8a35-ddf9-4fc8-8e55-e72637de6aa2
Protocol(s): S1115
Cook E, Anderson K, Zell J, Brown P: Challenges of recruiting native Alaskans to a nationwide
colorectal cancer prevention study. American Society of Preventive Oncology Annual Meeting
(ASPO), Memphis, TN, Mar 2013. http://www.aspo.org/annual_meeting
Protocol(s): S0820
Genitourinary Cancer
CALGB/Alliance
Hertz DL, Owzar K, Halabi S, Kelly WK, Zembutsu H, Jiang C, Patel JN, Watson D, Shterev I, Kroetz
DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Small EJ, Febbo PG, Nakamura Y, Kubo
M, Ratain MJ, McLeod H: A genome-wide association study (GWAS) of docetaxel-induced peripheral
neuropathy in CALGB 90401 (Alliance). J Clin Oncol 2013; 31(15 suppl): Abst. 11053. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/11053?sid=30653c8d-10d0-4e94-b908-7356ebd3c64b
Other Participant(s) in the Trial: ECOG Protocol(s): CALGB-90401
Nixon AB, Halabi S, Shterev I, Starr MD, Brady JC, Dutcher JP, Hopkins JO, Hurwitz HI, Small EJ,
Rini BI, Febbo PG, George DJ: Identification of predictive biomarkers of overall survival (OS) in
patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or
without bevacizumab (B): Results from CALGB 90206 (Alliance). J Clin Oncol 2013; 31(15 suppl):
Abst. 4520. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/4520?sid=a910434a-08d0-4365-9c6c-4ea10a5b5251
Other Participant(s) in the Trial: ECOG, NCIC Clinical Trials Group Protocol(s): CALGB-90206
Smith MR, Halabi S, Ryan CJ, Stadler WM, Hussain A, Vogelzang NJ, Hauke RJ, Sanford BL, Small
EJ: Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone
metastases: Results of CALGB 90202 (Alliance). J Clin Oncol 2013; 31(6 suppl): Abst. 27. http://meeting.ascopubs.org/cgi/content/abstract/31/6_suppl/27?sid=ebf90eba-f9fa-4bc6-804f-c8912314d7de
Other Participant(s) in the Trial: ECOG, NCIC Clinical Trials Group, RTOG, SWOG Protocol(s): CALGB-90202 ECOG
McDermott DF, Manola J, Pins MR, Flaherty KT, Atkins MB, Dutcher JP, George DJ, Margolin KA,
DiPaola RS: The BEST trial (E2804): A randomized phase II study of VEGF, RAF kinase, and mTOR
combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem)
in advanced renal cell carcinoma (RCC). J Clin Oncol 2013; 31(15 suppl): Abst. 345. http://meeting.ascopubs.org/cgi/content/abstract/31/6_suppl/345?sid=87c62cf2-97ad-4db8-a9b4-47bee1a5f95c
Other Participant(s) in the Trial: CALGB/Alliance, SWOG Protocol(s): E2804
NCI-Sponsored Groups Meetings Report 11 of 26
Summer 2013
RTOG
Bruner DW, Pugh S, Pisansky TM, Greenberg R, Pervez N, Reed DR, Rosenthal SA, Mowat RB,
Raben A, Buyyounouski M, Kachnic LA: Preliminary Results of RTOG 0831, Randomized, Double-
Blinded, Placebo-Controlled Trial of Tadalafil in the Prevention of Erectile Dysfunction in Patients
Treated with Radiotherapy for Prostate Cancer. J Clin Oncol 2013; 31(15 suppl): Abst. 9525. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/9525?sid=a0e44b7d-e27d-4a31-bec8-db3c457fd773
Protocol(s): RTOG-0831 SWOG
Baumann BC, He J, Hwang W, Tucker K, Lerner SP, Tangen CM, Herr HW, Guzzo T, Malkowicz
SB, Christodouleas J: Risk stratification for local-regional failure after cystectomy. American
Urological Association, San Diego, CA, May 2013. Abst. 1628. http://www.aua2013.org/abstracts/archive/abstracts_Baumann_Brian.cfm
Other Participant(s) in the Trial: CALGB/Alliance, ECOG Protocol(s): INT-0080 (SWOG-8710)
Goodman PJ, Thompson IM, Tangen CM, Parnes HL, Godley PA, Ford LG: Long-term survival of
subjects in the prostate cancer prevention trial. J Clin Oncol 2013; 31(6 suppl): Abst. 10. http://meeting.ascopubs.org/cgi/content/abstract/31/6_suppl/10?sid=0b66a628-dd0a-4bd5-bacb-09fcc1d016a0
Other Participant(s) in the Trial: CALGB/Alliance Protocol(s): SWOG-9217
Guertin KA, LaBarre J, Agler AH, Parker R, Arnold KB, Hartline J, Goodman PJ, Tangen C, Minasian
L, Lippman SM, Klein E, Cassano PA: The response to vitamin E supplementation. American Society
for Nutrition, Scientific Sessions & Annual Meeting at Experimental Biology, Boston, MA, Apr 2013. http://www.nutrition.org/education-and-professional-development/archived-content-from-past-meetings-and-professional-development-events/asn-at-eb-2013/
Protocol(s): S0000C
Hermos JA, Arnold KB, Cook ED, Anderson KB, Probstfield JL: Factors associated with retention of
African-American and white participants in a prostate cancer prevention trial. Society for Clinical
Trials, Boston, MA, May 2013. http://www.sctweb.org/public/meetings/2013/home.cfm
Other Participant(s) in the Trial: CALGB/Alliance, ECOG, NCCTG/Alliance, RTOG Protocol(s): S0000
Tang W, Guertin KA, Arnold KB, Crowley JJ, Hartline JA, Goodman PJ, Tangen CM, Minasian LM,
Lippman SM, Klein E, Cassano PA: A prudent diet attenuates lung function decline in cigarette
smokers. American Society for Nutrition, Scientific Sessions & Annual Meeting at Experimental
Biology, Boston, MA, Apr 2013. http://www.nutrition.org/education-and-professional-development/archived-content-from-past-meetings-and-professional-development-events/asn-at-eb-2013/
Protocol(s): S0000C
Yee M, Hartline J, Goodman P, Darke A, Crowley J: Will transitioning from paper to Web-based data
collection be successful in an aging male study population? American Society of Preventive Oncology
Annual Meeting (ASPO), Memphis, TN, Mar 2013. http://www.aspo.org/annual_meeting
Other Participant(s) in the Trial: CALGB/Alliance, ECOG, NCCTG/Alliance, RTOG Protocol(s): S0000
NCI-Sponsored Groups Meetings Report 12 of 26
Summer 2013
Gynecologic Cancer
GOG
Bishop EA, Java J, Moore KN, Walker J: Pathologic and treatment outcomes among a geriatric
population of endometrial cancer patients: A GOG ancillary data study. Gynecologic Oncology 2013;
130(1): Pg. e19. http://www.sciencedirect.com/science/article/pii/S0090825813003624
Protocol(s): GOG-LAP2
Chan JK, Java J, Monk BJ, Coleman RL, Birrer MJ, Aghajanian C, Bookman MA, Burger RA:
Patterns of cross-over to anti-angiogenesis agents in recurrent ovarian cancer patients: An analysis of a
Gynecologic Oncology Group ancillary data study. Gynecologic Oncology 2013; 130(1): Pg. e122. http://www.sciencedirect.com/science/article/pii/S0090825813006070
Protocol(s): GOG-0218
Coleman R, Sill M, Aghajanian C, Gray HS, Tewari K, Rubin S, Rutherford T, Chan J, Swisher E: A
phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of
persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who
carry a germline BRCA1 or BRCA2 mutation - a Gynecologic Oncology Group. Gynecologic
Oncology 2013; 130(1): Pg. e168. http://www.sciencedirect.com/science/article/pii/S009082581300721X
Protocol(s): GOG-0280
Coleman R, Sill M, Thaker P, DeGeest K, Street D, McGuire W, Rotmensch J: A phase II evaluation
of AZD6244, a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial
cancer: A GOG study. Gynecologic Oncology 2013; 130(1): Pg. e12-e13. http://www.sciencedirect.com/science/article/pii/S0090825813003429
Protocol(s): GOG-0229H
Coleman RL, Burger RA, Brady M, Bookman MA, Fowler J, Birrer MJ, Fleming G, Mannel R, Monk
BJ: Analysis of survivorship in high-risk patients treated on GOG-218. Gynecologic Oncology 2013;
130(1): Pg. e112-e113. http://www.sciencedirect.com/science/article/pii/S0090825813005829
Protocol(s): GOG-0218
DuPont NC, Brady MF, Burger RA, Monk BJ: Prognostic significance of ethnicity and age in
advanced stage ovarian cancer: An analysis of GOG-218. Gynecologic Oncology 2013; 130(1): Pg.
e21-e22. http://www.sciencedirect.com/science/article/pii/S0090825813003697
Protocol(s): GOG-0218
Eskander RN, Java J, Tewari KS, Burger RA, Monk BJ: Negative survival impact associated with >25
day interval from surgical cytoreduction to initiation of systemic therapy in advanced ovarian
carcinoma: A Gynecologic Oncology Group ancillary data study. Gynecologic Oncology 2013; 130(1):
Pg. e22-e23. http://www.sciencedirect.com/science/article/pii/S0090825813003715
Protocol(s): GOG-0218
NCI-Sponsored Groups Meetings Report 13 of 26
Summer 2013
Farley JH, Brady WE, Birrer MJ, Gersheonson DM, Fleming GF: An evaluation of survival of ovarian
cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: A
Gynecologic Oncology Group experience. J Clin Oncol 2013; 31(15 suppl): Abst. 5534. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/5534?sid=22e1cc96-1545-4e87-a8fb-e17adb4ddcfd
Other Participant(s) in the Trial: NCCTG/Alliance, SWOG Protocol(s): GOG-0095, GOG-0114, GOG-0128G, GOG-0152, GOG-0162, GOG-0172, GOG-0175, GOG-0182, GOG-111
Hess LM, Huang H, Robinson WR, Johnson R, Alberts DS: Cognitive function during chemotherapy
for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: a Gynecologic
Oncology Group study. Gynecologic Oncology 2013; 130(1): Pg. e6-e7. http://www.sciencedirect.com/science/article/pii/S0090825813003272
Protocol(s): GOG-0256
Horowitz NS, Miller, A, Rungruang B, Richard S, Rodriguez N, Bookman M, Hamilton CA, Maxwell
GL, Krivak TC: Impact of preoperative and pretreatment CA-125 on survival in women with optimally
cytoreduced advanced stage epithelial ovarian or primary peritoneal carcinoma: a GOG Ancillary Data
Study. Gynecologic Oncology 2013; 130(1): Pg. e20. http://www.sciencedirect.com/science/article/pii/S0090825813003661
Protocol(s): GOG-0182
Huh WK, Brady WE, Moore KN, Lankes HA, Monk BJ, Aghajanian C, Dizon DS, Fracasso PM: A
phase II study of live-attenuated listeria monocytogenes immunotherapy (ADXS11-001) in the
treatment of persistent or recurrent cancer of the cervix. J Clin Oncol 2013; 31(15 suppl): Abst.
TSP3121. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/TPS3121?sid=949ab761-59af-467e-ab2e-fce772f5acd4
Protocol(s): GOG-0265
Milam MR, Java J, Parker LP, Metzinger D, Coleman RL, Walker JL: Survival in early stage
endometrioid endometrial cancer risk groups: a Gynecologic Oncology Group ancillary data study.
Gynecologic Oncology 2013; 130(1): Pg. e23. http://www.sciencedirect.com/science/article/pii/S0090825813003727
Protocol(s): GOG-LAP2
Miller C, Miller A, Hamilton C, Secord AA, Havrilesky L, Muggia F, Farley J: An evaluation of
molecular markers that predict maximal surgical cytoreduction: A Gynecologic Oncology Group trial.
Gynecologic Oncology 2013; 130(1): Pg. e-20. http://www.sciencedirect.com/science/article/pii/S009082581300365X
Other Participant(s) in the Trial: ECOG, SWOG Protocol(s): GOG-0114, GOG-0132
Miller D, Blessing JA, Ramondetta L, Pham H, Tewari K, Landrum L, Brown J, Mannel R:
GOG0076-GG: A limited access phase II trial of pemetrexed (LY231514) (NSC #698037) in
combination with cisplatin (NSC #119875) in the treatment of advanced, persistent, or recurrent
carcinoma of the cervix—A Gynecologic Oncology Group study. J Clin Oncol 2013; 31(15 suppl):
Abst. 5527. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/5527?sid=a6734e19-dfc4-4df4-ba5a-3b1ea4e3b07e
Protocol(s): GOG-0076-GG
NCI-Sponsored Groups Meetings Report 14 of 26
Summer 2013
Monk BJ, Brady WE, Lankes HA, Facciabene A, Manjarrez K, Hershberg RM, Fracasso PM, Bell-
McGuinn KM, Walker JL, McCourt CK, Aghajanian C, Coukos G: VTX-2337, a TLR8 agonist, plus
chemotherapy in recurrent ovarian cancer: Preclinical and phase I data by the Gynecologic Oncology
Group. J Clin Oncol 2013; 31(15 suppl): 3077. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/3077?sid=f0862b02-5848-4837-a425-3d32b7d64bd8
Protocol(s): GOG-9925
Randall L, Burger R, Nguyen H, Kong G, Bookman M, Fleming G, Monk B, Mannel R, Birrer M:
Time from completion of chemotherapy to disease progression as a clinically relevant endpoint in
women with epithelial ovarian, primary peritoneal, and fallopian tube cancers treated with and without
bevacizumab. Gynecologic Oncology 2013; 130(1): Pg. e120. http://www.sciencedirect.com/science/article/pii/S0090825813006021
Protocol(s): GOG-0218
Randall LM, Burger RA, Nguyen H, Kong G, Bookman MA, Fleming GF, Monk BJ, Mannel RS,
Birrer MJ: Outcome differences in patients with advanced epithelial ovarian, primary peritoneal and
fallopian tube cancers treated with and without bevacizumab. Gynecologic Oncology 2013; 130(1): Pg.
e33-e34. http://www.sciencedirect.com/science/article/pii/S0090825813003958
Protocol(s): GOG-0218
Rocconi RP, Fernandez JR, Brady WE, Darcy KM, Goodfellow PJ, Lankes H, Trichler D, Ramirez NC,
Creasman W, Alvarez RD: The role of racial genetic admixture with endometrial cancer outcomes: A
Gynecologic Oncology Group study. Gynecologic Oncology 2013; 130(1): Pg. e168-e169. http://www.sciencedirect.com/science/article/pii/S0090825813007221
Protocol(s): GOG-0210, GOG-8022
Rose PG, Java J, Whitney C, Keys H, Lanciano R, Thomas G: Locally advanced adenocarcinoma and
adenosquamous carcinoma of the cervix compared to squamous cell carcinoma of the cervix in
Gynecologic Oncology Group trials of chemoradiation. J Clin Oncol 2013; 31(15 suppl): Abst. 5530. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/5530?sid=1281001e-bf60-47d7-a769-ee2cf36d667d
Other Participant(s) in the Trial: SWOG Protocol(s): GOG-0120, GOG-0123, GOG-0165, GOG-0191, GOG-85
Rungruang B, Miller A, Krivak TC, Horowitz NS, Rodriguez N, Hamilton CA, Bookman MA,
Maxwell GL, Richard SD: What is the role of retroperitoneal exploration in optimally debulked stage
III C epithelial ovarian cancer? A Gynecologic Oncology Group ancillary data study. Gynecologic
Oncology 2013; 130(1): Pg. e9. http://www.sciencedirect.com/science/article/pii/S009082581300334X
Protocol(s): GOG-0182
Tewari D, Java JJ, Salani R, Armstrong D, Markman M, Herzog T, Monk BJ, Chan JK: Long-term
survival advantage of intraperitoneal chemotherapy treatment in advanced ovarian cancer: An analysis
of a Gynecologic Oncology Group ancillary data study. Gynecologic Oncology 2013; 130(1): Pg. e4. http://www.sciencedirect.com/science/article/pii/S0090825813003211
Other Participant(s) in the Trial: ECOG, SWOG Protocol(s): GOG-0114, GOG-0172
NCI-Sponsored Groups Meetings Report 15 of 26
Summer 2013
Tewari K, Sill MW, Long HJ, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM,
Michael HE, Monk BJ: Incorporation of bevacizumab in the treatment of recurrent and metastatic
cervical cancer: A phase III randomized trial of the Gynecologic Oncology Group. J Clin Oncol 2013;
31(18 suppl): Abst. 3. http://meeting.ascopubs.org/cgi/content/abstract/31/18_suppl/3?sid=525bfeb4-f569-48ca-b27d-8d911e67daf2
Other Participant(s) in the Trial: ECOG, GEICO Protocol(s): GOG-0240
Tewari KS, Sill MW, Monk BJ, Long H, Ramondetta L, Landrum L, Oaknin A, Reid T, Leitao M,
Michael H: Phase III randomized clinical trial of cisplatin plus paclitaxel vs. the non-platinum
chemotherapy doublet of topotecan plus paclitaxel in women with recurrent, persistent, or advanced
cervical carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology 2013; 130(1): Pg. e2. http://www.sciencedirect.com/science/article/pii/S0090825813003168
Other Participant(s) in the Trial: ECOG, GEICO Protocol(s): GOG-0240
Head and Neck Cancer ACOSOG/Alliance
Lai SY, Agrawal A, Civantos FJ: Utilization of Receptor Targeted Technetium Tc 99m Tilmanocept
(Lymphoseek Injection) to Identify and Evaluate the Pathological Status of Sentinel Lymph Nodes vs.
Elective Neck Dissection in Patients with Intraoral Squamous Cell Carcinoma: A Preliminary
Performance Evaluation Against Technetium Tc 99m Sulfur Colloid in the ACOSOG-Z0360 Study.
Annals of Surgical Oncology 2013; 20(1 suppl): S108; Abst. P226. http://expo.jspargo.com/exhibitor/web/SSOAbstracts.pdf
Protocol(s): ACOSOG-Z0360 ECOG
Burtness BA, Lee J, Yang D, Zhu F, Garcia JJ, Forastiere AA, Chung CH: Activity of cetuximab (C)
in head and neck squamous cell carcinoma (HNSCC) patients (pts) with PTEN loss or PIK3CA
mutation treated on E5397, a phase III trial of cisplatin (CDDP) with placebo (P) or C. J Clin Oncol
2013; 31(15 suppl): Abst. 6028. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/6028?sid=e4f4e8aa-1ecc-45f6-9ebf-6985f9a6e9ac
Protocol(s): E5397
Marur S, Lee J, Cmelak AJ, Zhao W, Westra WH, Chung CH, Gillison ML, Gilbert J, Bauman JE,
Wagner LI, Ferris RL, Trevarthen DR, Colevas AD, Jahagirdar BN, Burtness BA: ECOG 1308: A
phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose
IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP). J
Clin Oncol 2013; 31(15 suppl): Abst. 5566. http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5566?sid=efab4d5f-940f-4915-ad04-9684f8b77397
Protocol(s): E1308
Mehra R, Egloff AM, Li S, Yang D, Wang L, Zhu F, Forastiere AA, Burtness BA, Argiris A: Analysis
of HPV and ERCC1 in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M
SCCHN). J Clin Oncol 2013; 31(15 suppl): Abst. 6006. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/6006?sid=2c9ec058-10f6-4997-b2c6-19066801bc3c
Protocol(s): E1395, E3301
NCI-Sponsored Groups Meetings Report 16 of 26
Summer 2013
Psyrri A, Lee J, Vassilakopoulou M, Pectasides E, Burtness BA, Rimm D, Wanebo HJ, Forastiere AA:
Predictive biomarkers in a phase II trial of weekly carboplatin (CBDCA), paclitaxel (P), and cetuximab
(C) induction and chemoradiation (CRT) in patients (pts) with resectable stage III/IVa,b head and neck
squamous cell carcinoma (HNSCC): Eastern Cooperative Oncology Group E2303. J Clin Oncol 2013;
31(15 suppl): Abst. 6081. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/6081?sid=14d325cd-837b-4afb-826e-63b7850b5b04
Protocol(s): E2303
Weidhaas JB, Lee J, Slebos RJ, Howard J, Perez J, Gilbert J, Nallur SV, Paranjape T, Garcia JJ,
Burtness BA, Forastiere AA, Chung CH: Association of the 3'-untranslated region KRAS-variant with
cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell
carcinoma. J Clin Oncol 2013; 31(15 suppl): Abst. 6016. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/6016?sid=740a3dec-f680-4685-aee3-fd70c7c2d60a
Protocol(s): E5397 NCCTG/Alliance
Miller R, Leenstra J, Qun R, Martenson J, Dornfeld J, Bearden J, Puri D, Stella P, Foote R, Loprinzi C:
N09C6 (Alliance) - A Phase 3, Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in
the Treatment of Acute Oral Mucositis Pain in Patients Receiving Head and Neck Radiation Therapy
With or Without Chemotherapy. Int J Radiat Oncol Biol Phys 2013; 85(1): 21; Abst. LBA1. http://www.redjournal.org/article/S0360-3016(12)03772-8/fulltext
Protocol(s): N09C6 RTOG
Chung CH, Zhang Q, Kong C, Harris J, Ang KK, Harari PM, Wang D, Redmond KP, Shenouda G,
Trotti A, Raben D, Gillison ML, Jordan R, Le QT: p16 Expression as a Human Papillomavirus (HPV)-
Independent Prognostic Biomarker of Non-Oropharyngeal Squamous Cell Carcinoma (non-OPSCC). J
Clin Oncol 2013; 31(15 suppl): Abst. 6007. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/6007?sid=21f76982-2274-4b2a-bee9-bd39a58033f9
Protocol(s): RTOG-0129, RTOG-0234, RTOG-0522
Rosenthal D, Zhang Q, Kies M, Truong MT, Jordan R, Harari P, Le WT: Seamless Phase II/III Trial
Design with Survival and PRO Endpoints for Treatment Selection: Case Study of RTOG 1216. J Clin
Oncol 2013; 31(15 suppl): Abst. TPS6099. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/TPS6099?sid=02bb23f9-9f67-431b-b70f-a76a9f26579d
Other Participant(s) in the Trial: ECOG Protocol(s): RTOG-1216
Leukemia, Myelodysplasia, and Transplantation
CALGB/Alliance
Niederwieser C, Kohlschmidt J, Maharry K, Mrózek K, Metzeler KH, Volinia S, Yan P, Frankhouser
D, Whitman SP, Becker H, Eisfeld A-K, Schwind S, Curfman J, Wu Y-Z, Baer MR, Powell BL, Kolitz
JE, Moore JO, Carter TH, Marcucci G, Bloomfield CD: High expression of DNMT3B negatively
impacts on clinical outcome of older patients (pts) with primary cytogenetically normal (CN) acute
myeloid leukemia (AML) [CALGB 20202 (Alliance)]. European Hematology Association Congress,
Stockholm, Sweden, Jun 2013. Abst. S1168. https://b-com.mci-group.com/EventProgramme/EHA18.aspx (NOT A DIRECT LINK)
Protocol(s): CALGB-20202
NCI-Sponsored Groups Meetings Report 17 of 26
Summer 2013
Wang X, Owzar K, Gupta P, Larson RA, Mulkey F, Miller AA, Lewis LD, Hurd D, Vij R, Ratain MJ,
Murry D: Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB
10105 (Alliance). Clin Pharmacol Ther 2013; 93(1 suppl): S82; Abst. PII-84. http://www.nature.com/clpt/journal/v93/n1s/pdf/clpt2012256a.pdf
Protocol(s): CALGB-10105 COG
Bhatla T, Wang J, Morrison D, Jones C, Raetz EA, Burke MJ, Brown PA, Loh ML, Hunger SP,
Carroll WL: Evolution of the histone code in relapsed acute lymphoblastic leukemia (ALL). Pediatr
Blood Cancer 2013; 60(2 suppl): Pg. S40 (Poster 616). http://hsl.med.nyu.edu/facbib-results/author/bhatlt01?src=medical
Protocol(s): AALL0331
Mast K, Taub JW, Mosse C, Matthew P, Hitzler JH, Alonzo T, Jones H, Gamis AS, Head DR:
Morphology of myeloid leukemia of down syndrome. Modern Pathology 2013; 26(2s suppl): 345A;
Abst. 1446. http://www.nature.com/modpathol/journal/v26/n2s/pdf/modpathol201313a.pdf
Protocol(s): AAML0431
Mattano LA, Devidas M, Friedmann AM, Winick NJ, Raetz EA, Hunger SP, Carroll WL, Maloney
KW: Effect of dexamethasone (DEX) dose modification on osteonecrosis (ON) risk associated with
intensified therapies for standard risk acute lymphoblastic leukemia (SR-ALL): A report from the
Children’s Oncology Group (COG) study AALL0331. J Clin Oncol 2013; 31(suppl): Abst. 10002. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/10002?sid=8120ae93-4f01-48ba-a54a-e714fd89c2c4
Protocol(s): AALL0331 ECOG
Zeidan AM, Sun Z, Prebet T, Greenberg P, Juckett MB, Smith MR, Paietta EM, Gabrilove JL, Erba
HP, Gore SD, Tallman MS: Application of the French prognostic score (FPS) to assess overall survival
(OS) in a U.S.-based cohort of patients (pts) treated with azacitidine (Aza). J Clin Oncol 2013; 31(15
suppl): Abst. 7126. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7126?sid=9105e93a-53f7-4691-ab45-c046757e2f6e
Protocol(s): E1905
Zeidan AM, Sun Z, Prebet T, Greenberg P, Juckett MB, Smith MR, Paietta EM, Grabilove J, Erba HP,
Gore SD, Tallman MS: Application of the French Prognostic Score to Assess Overall Survival in a US-
Based Cohort of Patients Treated with Azacitidine. Leuk Res 2013; 37(1 suppl): S79-S80; Abst. P-124. http://mds.ekonnect.co/MDS_402/poster_60829/program.aspx
Protocol(s): E1905 SWOG
Advani AS, McDonough S, Copelan EA, Willman CL, Mulford D, List AF, Sekere MA, Othus M,
Erba HP, Appelbaum FR: SWOG S0919: A phase II study of idarubicin and cytarabine in combination
with pravastatin for relapsed acute myeloid leukemia (AML). J Clin Oncol 2013; 31(15 suppl): Abst.
7028. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7028?sid=2dd82822-93ed-482a-b494-a65bc141dd1b
Protocol(s): S0919
NCI-Sponsored Groups Meetings Report 18 of 26
Summer 2013
Cesano A, Willman CL, Kopecky KJ, Putta S, Cohen A, Marimpietri C, Atwater SK, Appelbaum FR,
Radich J: Deregulation of stem cell factor (SCF)-AKT-S6 pathway in diagnostic AML samples is
associated with disease-free survival: Results of a verification study. European Hematology
Association Congress, Stockholm, Sweden, Jun 2013. http://www.postersessiononline.eu/pr/aula_poster.asp?congreso=602733790
Protocol(s): S0112, S0301, SWOG-9031, SWOG-9333
Lung Cancer
ACOSOG/Alliance
Fernando HC, Landreneau RJ, Mandrekar SJ, Nichols FC, Hillman SL, Heron DE, Meyers BF,
DiPetrillo TA, Jones DR, Starnes SL, Tan AD, Daly B, Putnam JB: Impact of brachytherapy on local
recurrence after sublobar resection: Results from ACOSOG Z4032 (Alliance), a phase III randomized
trial for high-risk operable non-small cell lung cancer (NSCLC). J Clin Oncol 2013; 31(15 suppl):
Abst. 7502. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7502
Protocol(s): ACOSOG-Z4032
Kent MS, Landreneau RJ, Mandrekar SJ, Nichols FC, DiPetrillo TA, Meyers BF, Heron DE, Putnam
JB, Jones DR, Starnes SL, Daly B, Tan AD, Fernando HC: Factors impacting oncologic outcomes after
sublobar pulmonary resection: Results from ACOSOG Z4032 (Alliance), a randomized trial for high-
risk operable non-small cell lung cancer (NSCLC). J Clin Oncol 2013; 31(15 suppl): Abst. 7524. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7524
Protocol(s): ACOSOG-Z4032
Su S, Scott WJ, Allen MS, Darling GE, Decker PA, McKenna RJ, Landreneau RJ, Jones DR, Inculet RI,
Meyers BF: Long-term surgical outcomes of 1018 patients with early stage NSCLC in ACOSOG Z0030
trial. American Association for Thoracic Surgery (AATS), Minneapolis, MN, May 2013. Abst. LB6. http://www.aats.org/annualmeeting/Program-Books/2013/LB6.cgi
Protocol(s): ACOSOG-Z0030 ACRIN
Commean PK, Rathmell JM, Riley TL, Clark KW, Prior FW: A query tool for investigator access to
the metadata and CT images of the National Lung Screening Trial. Society for Imaging Informatics in
Medicine (SIIM), Grapevine-Dallas, TX, Jun 2013. http://www.siim2013.org/abstracts/3_BADM_Commean.html
Protocol(s): ACRIN-6654
Gareen IF, Park ER, Gorelick J, Japuntich S, Lennes IT, Baum S, Sicks J, Rigotti N: The effects of
physician-delivered brief smoking cessation on ACRIN/NLST participants’ smoking behaviors. J Clin
Oncol 2013; 31(15 suppl): Abst. 7525. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7525
Protocol(s): ACRIN-6654
Lathan C, Kumar P, Gareen IF, Gorelick J, Sicks J, Hyland K, Park ER: Racial differences in
perceived risk in participants enrolled in the American College of Radiology (ACRIN-6654) arm of the
National Lung Screening Trial (NLST). J Clin Oncol 2013; 31(15 suppl): Abst. 1563. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/1563
Protocol(s): ACRIN-6654
NCI-Sponsored Groups Meetings Report 19 of 26
Summer 2013
Streck JM, Nichter M, Ostroff JS, Rigotti NA, Gareen I, Hyland K, Park ER: Exploring risk
perceptions following lung screening: A qualitative study among ACRIN National Lung Screening
Trial (NLST) participants. Society for Research on Nicotine and Tobacco (SRNT), Boston, MA, Mar
2013. 51; PA14-1. http://www.srnt.org/conferences/SRNT_2013_Abstracts_I-Modified.pdf
Protocol(s): ACRIN-6654 Alliance
Foster NR, Renfro LA, Schild SE, Redman MW, Wang XF, Dahlberg, SE, Ding K, Bradbury PA,
Ramalingam SS, Gandara DR, Vokes EE, Adjei AA, Mandrekar SJ: Multitrial evaluation of
progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in previously
untreated extensive-stage small cell lung cancer (ES-SCLC): An Alliance-led analysis. J Clin Oncol
2013; 31(15 suppl): Abst. 7510. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7510?sid=71e4c947-7e48-4d49-82ae-cb1c9c1b88ea
Other Participant(s) in the Trial: CALGB/Alliance, NCCTG/Alliance, SWOG Protocol(s): CALGB-30103, CALGB-9033, CALGB-9732, NCCTG-862051, NCCTG-892051, NCCTG-932053 CALGB/Alliance
Ready NE, Pang HH, Gu L, Otterson GA, Thomas SP, Miller AA, Baggstrom MQ, Masters GA,
Graziano SL, Crawford J, Bogart J, Vokes EE: Chemotherapy with or without maintenance sunitinib
for untreated extensive-stage small cell lung cancer: A randomized, placebo controlled phase II study
CALGB 30504 (ALLIANCE). J Clin Oncol 2013; 31(15 suppl): Abst. 7506. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7506?sid=3204ebb7-e5d3-4684-ab2e-9ed3bee6bc33
Protocol(s): CALGB-30504
Stinchcombe TE, Sholl LM, Wang X, Gu L, Socinski MA, Rodig SJ, Capelletti M, Crawford J,
Edelman MJ, Villalona-Calero MlA, Kratzke R, Vokes EE, Miller VA, Janne PA: An analysis of the
prevalence of HER2 and KRAS mutations, and ALK rearrangements and clinical outcomes in Cancer
and Leukemia Group B [CALGB (Alliance)] trial 30406 in advanced non-small cell lung cancer
(NSCLC). J Clin Oncol 2013; 31(15 suppl): Abst. 8039. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/8039?sid=7a0ce0eb-b5ee-4fdc-a77f-71be781bb655
Protocol(s): CALGB-30406 ECOG
Aggarwal C, Dahlberg SE, Hanna NH, Kolesar J, Hirsch F, Ramalingam SS, Schiller JH: Exploratory
biomarker analyses from ECOG 4508: Three-arm randomized phase II study of carboplatin (C) and
paclitaxel (P) in combination with cetuximab (CET), IMC-A12, or both for advanced non-small cell
lung cancer (NSCLC) patients (pts). J Clin Oncol 2013; 31(15 suppl): Abst. 8106. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/8106?sid=bc974b89-3096-4bfa-bfd2-3c6bf3370c13
Protocol(s): E4508
Ahn DH, Dahlberg SE, Sandler AB, Perry MC, Schiller JH, Brahmer JR, Johnson DH, Gerber DE:
Association between baseline tumor dimensions and survival in advanced non-small cell lung cancer
(NSCLC). J Clin Oncol 2013; 31(15 suppl): Abst. 8046. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/8046?sid=8d6b8803-dcde-4593-8709-41376a4411f5
Protocol(s): E4599
NCI-Sponsored Groups Meetings Report 20 of 26
Summer 2013
Belani CP, Dahlberg SE, Rudin CM, Fleisher M, Chen HX, Takebe N, Ramalingam SS, Schiller JH:
Three-arm randomized phase II study of cisplatin and etoposide (CE) versus CE with either
vismodegib (V) or cixutumumab (Cx) for patients with extensive stage-small cell lung cancer (ES-
SCLC) (ECOG 1508). J Clin Oncol 2013; 31(15 suppl): Abst. 7508. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7508?sid=bea83189-fbee-4190-8a8e-952401aab275
Protocol(s): E1508 NCCTG/Alliance
Molina JR, Mandrekar SJ, Dy G, Aubry MC, Ziegler KA, Dakhil SR, Sachs BA, Nieva JJ, Schild SE,
Burroughs K, Williams A, Rudin CM, Adjei AA: A randomized double-blinded phase II study of the
Seneca Valley Virus (NTX-010) vs placebo for patients with extensive stage SCLC (ES-SCLC) who
were stable or responding after at least 4 cycles of platinum-based chemotherapy: NCCTG N0923
(Alliance) Study. J Clin Oncol 2013; 31(15 suppl): Abst. 7509. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7509?sid=f86c42bd-cca1-4de3-8743-75e37bd17763
Other Participant(s) in the Trial: ACOSOG/Alliance, CALGB/Alliance, ECOG Protocol(s): N0923 RTOG
Bradley JD, Paulus R, Komaki R, Masters RA, Forster K, Schild SE, Bogart J, Garces YI, Narayan S,
Kavadi V, Nedzi LA, Michalski JM, Johnson D, MacRae RM, Curran WJ, Choy H: A Randomized
Phase III Comparison of Standard-dose (60 Gy) versus High-dose (74 Gy) Conformal
Chemoradiotherapy +/- Cetuximab for Stage III Non-small Cell Lung Cancer: Results on Radiation
Dose in RTOG 0617. J Clin Oncol 2013; 31(15 suppl): Abst. 7501. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7501?sid=edeacee8-f51f-416f-9ee2-a7d2c0c8b8fa
Other Participant(s) in the Trial: CALGB/Alliance, ECOG, NCCTG/Alliance Protocol(s): RTOG-0617
Timmerman R, Paulus R, Pass HI, Gore E, Edelman MJ, Galvin JM, Choy H, Straube W, Nedzi LA,
McGarry R, Robinson CG, Schiff P, Bradley JD: RTOG 0618: Stereotactic Body Radiation Therapy
(SBRT) to Treat Operable Early-stage Lung Cancer Patients. J Clin Oncol 2013; 31(15 suppl): Abst.
7523. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7523?sid=f4aa2776-f41c-45e9-829d-ea636e8971b6
Protocol(s): RTOG-0618 SWOG
Kernstine K, Moon J, Kraut M, Pisters K, Sonett J, Rusch V, Thomas CR, Waddell T, Jett J, Lyss A,
Keller S, Gandara D: Induction Chemoradiotherapy Followed By Consolidation Cytotoxic Therapy for
Superior Sulcus (Pancoast tumors) Non-Small Cell Lung Cancer: A Southwest Oncology Group
(SWOG)-Coordinated Feasibility Phase II Intergroup Trial (S0220). Society of Thoracic Surgeons, Los
Angeles, CA, Jan 2013. http://conference-cast.com/STS/common/presentations.aspx/1/2/30
Other Participant(s) in the Trial: ACOSOG/Alliance, CALGB/Alliance, ECOG, NCCTG/Alliance, NCIC Clinical Trials Group Protocol(s): S0220
NCI-Sponsored Groups Meetings Report 21 of 26
Summer 2013
Lara PN, Moon J, Redman MW, Kelly K, Allen JW, Gitlitz BJ, Mack PC, Gandara DR: Relevance of
platinum (plat) sensitivity status in previously treated extensive-stage small cell lung cancer (ES-
SCLC) in the modern era: A patient level analysis of SWOG trials. J Clin Oncol 2013; 31(15 suppl):
Abst. 7511. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7511?sid=3a1cfd25-0bd8-405d-8146-0386698af5d3
Protocol(s): S0327, S0435, S0802 Tsao A, Moon J, Wistuba I, Vogelzang N, Kalemkerian G, Redman M, Gandara D: A phase I study of
cediranib (NSC #732208) in combination with cisplatin and pemetrexed in chemonaive patients with
malignant pleural mesothelioma (SWOG S0905). J Clin Oncol 2013; 31(15 suppl): Abst. 7527. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7527?sid=88c40e7b-9c69-4978-b981-03a642ffae27
Protocol(s): S0905
Lymphoma and Plasma Cell Disorders
CALGB/Alliance
Kaplan LD, Jung SH, Bartlett NC, Johnson J, Byrd J, Blum K, Stock W, LaCasce AS, Hsi E, Hurd D,
Czuczman MS, Cheson BD: Bortezomib maintenance (BM) vs consolidation (BC) following
aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell
lymphoma (MCL): CALGB 50403. Hematol Oncol 2013; 31(1 suppl): 126; Abst. 089. http://onlinelibrary.wiley.com/doi/10.1002/hon.2057/pdf
Protocol(s): CALGB-50403
Martin P, Jung S-H, Johnson J, Elstrom R, Bartlett NL, Blum K, Shea T, Leonard J, Cheson B:
CALGB 50803 (Alliance): A phase 2 trial of lenalidomide plus rituximab in patients with previously
untreated follicular lymphoma. Hematol Oncol 2013; 31(1 suppl): 117; Abst. 063. http://onlinelibrary.wiley.com/doi/10.1002/hon.2057/pdf
Protocol(s): CALGB-50803 ECOG
Advani RH, Li H, Hong F, Kahl BS, Varma G, Bousetta S, Pfeundschuh M, Ziepert M, Coiffier B:
Elderly International Prognostic Index in Diffuce Large B-Cell Lymphoma patients > 60 years treated
with RCHOP: international validation study using data from RICOVER-60 (German High-Grade Non-
Hodgkin Lymphoma Study Group) and LNH 98-5 (Groupe d’Etude de Lymphome d’Adultes).
Hematol Oncol 2013; 31(1 suppl): 171; Abst. 222. http://onlinelibrary.wiley.com/doi/10.1002/hon.2058/pdf
Other Participant(s) in the Trial: CALGB/Alliance, SWOG Protocol(s): E4494
Callander NS, Jacobus S, Weiss M, Kumar SK, Fonseca R, Siegel DS, Katz MS, Abonour R, Williams
ME, Greipp PR, Rajkumar V: Evaluation of protocol mandated testing in E4A03, a randomized phase
III study of CC-5013 plus dexamethasone versus CC-5013 plus low-dose dexamethasone in multiple
myeloma (MM). J Clin Oncol 2013; 31(15 suppl): Abst. E19517. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/e19517?sid=da801f4b-3d87-4cf2-9c5b-0f96320badc0
Protocol(s): E4A03
NCI-Sponsored Groups Meetings Report 22 of 26
Summer 2013
Swinnen LJ, Li H, Quon A, Gascoyne RD, Ranheim EA, Hong F, Habermann TM, Advani RH, Kahl
BS, Horning SJ: Response-adapted therapy and predictive value of mid-treatment PET scanning for
diffuse large B-cell lymphoma. ECOG Study E3404. Hematol Oncol 2013; 31(1 suppl): 101; Abst. 016. http://onlinelibrary.wiley.com/doi/10.1002/hon.2057/pdf
Protocol(s): E3404
Uno H: A hidden disjoint and issues on a standard survival data analysis in clinical trials.
Pharmaceutical & Regulatory Sciences Workshop, Boston, MA, May 2013. http://www.hsph.harvard.edu/prs-workshop/program/
Protocol(s): E4A03
Wagner H, Hong F, Gordon LI, Fisher RI, Bartlett NL, Desjardins P, Gascoyne RD, Stiff PJ, Cheson
BD, Caplan SN, Advani RH, Kahl BS, Friedberg J, Blum KA, Habermann TM, Tuscano JM, Hoppe
RT, Fitzgerald TJ, Laurie F, Horning SJ: Patterns of failure in a randomized phase III trial of ABVD
versus Stanford V +/- radiation therapy in locally extensive and advanced stage Hodgkin's lymphoma:
An intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). Hematol Oncol
2013; 31(1 suppl): 182; Abst. 256. http://onlinelibrary.wiley.com/doi/10.1002/hon.2058/pdf
Other Participant(s) in the Trial: CALGB/Alliance, NCIC Clinical Trials Group, SWOG Protocol(s): E2496 SWOG
Badari AR, Zaid MA, Unger JM, Rimsza LM, Marron M, Fisher RI, Miller TP, Stopeck AT: Markers
of angiogenesis and hypoxia to cell of origin (COO) subtypes of DLBCL: Correlative studies from
S0515, a phase II trial of R-CHOP plus bevacizumab. J Clin Oncol 2013; 31(15 suppl): Abst. 8562. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/8562?sid=cb6383a0-835d-4792-9e24-cbfa589775c0
Protocol(s): S0515
Dhodapkar MV, Sexton R, Waheed S, Usmani SZ, Papanikolaou XD, Nair BP, Petty N, Shaughnessy
JD, Hoering A, Crowley J, Orlowski RZ, Barlogie B: Clinical, genomic, and imaging predictors of
malignancy: Analysis of the first U.S. Cooperative Group prospective clinical trial in asymptomatic
monoclonal gammopathies (SWOG S0120). J Clin Oncol 2013; 31(15 suppl): Abst. 8515. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/8515?sid=aba74433-fdd6-4ca8-a64e-27da776eee47
Protocol(s): S0120
Press OW, LeBlanc M, Rimsza LM, Schoder H, Friedberg JW, Evens AM, Li H, Bartlett N, LaCasce
A, Sweetenham J, Evens A, Straus J, Noy A, Kostakoglul L, Grewal RK, Hsi ED, Gascoyne RD,
Cheson BD, Kahl B, Miller TP, Fisher RI: A phase II trial of response-adapted therapy of stage III-IV
Hodgkin lymphoma using early interim FDG-PET imaging: US Intergroup S0816. Hematol Oncol
2013; 31(1 suppl): 137; Abst. 124. http://onlinelibrary.wiley.com/doi/10.1002/hon.2057/pdf
Other Participant(s) in the Trial: CALGB/Alliance, ECOG Protocol(s): S0816
NCI-Sponsored Groups Meetings Report 23 of 26
Summer 2013
Melanoma/Skin Cancers
ECOG
Go RS, Lee S, Shin D, Callister SM, Jobe DA, Conry RM, Tarhini AA, Kirkwood JM: Phase II study
of low-dose peginterferon alfa-2b antiangiogenic therapy in patients with metastatic melanoma
overexpressing basic fibroblast growth factor: An Eastern Cooperative Oncology Group study
(E2602). J Clin Oncol 2013; 31(15 suppl): Abst. 9038. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/9038?sid=62934758-5f54-42ac-9b83-0adcdf18e179
Protocol(s): E2602
Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, Leming PD, Puzanov I,
Kirkwood JM: Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus
Ipi alone in metastatic melanoma: E1608. J Clin Oncol 2013; 31(15 suppl): Abst. CRA9007. http://meeting.ascopubs.org/cgi/content/abstract/31/18_suppl/CRA9007?sid=823b6c54-84f9-4cd9-bdec-1dfee158bd1f
Protocol(s): E1608
Other Cancer
ACRIN
Gareen I, Duan F, Snyder B, Sicks J: Response rate and time to response for patient reported outcomes
collected using a centralized system in two American College of Radiology Imaging Network cancer
screening trials. Amer J Epidemiol 2013; 177(11 suppl): S103; Abst. 411. http://aje.oxfordjournals.org/content/177/suppl_11
Protocol(s): ACRIN-6654, ACRIN-6664
CALGB/Alliance
Dressler LG, Deal AM, Watson D, Hollis D, Owzar K, Donohue K, Friedman PN, Ratain MJ, McLeod
HL: Participation in cancer pharmacogenomic studies in 8,456 patients registered to Cancer and
Leukemia Group B (Alliance) clinical trials. J Clin Oncol 2013; 31(15 suppl): Abst. 6501. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/6501?sid=e2b09ffa-e28f-45c1-afb9-2f6e54e008c2
Protocol(s): CALGB-40101, CALGB-50303, CALGB-80203, CALGB-80303, CALGB-80405, CALGB-90401
Gordon D, Liu Q, Kleinman B, Karrison T, Kelly M, Fleming G: Predictors of accrual success for
Cooperative Group trials: The Cancer and Leukemia Group B (Alliance) experience. J Clin Oncol
2013; 31(15 suppl): Abst. TPS6645. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/TPS6645?sid=68c9c943-2214-43b1-863e-06152963c0f5
Protocol(s): Multiple Trials ECOG
Chandwani KD, Zhao F, Morrow G, Deshields T, Manola J, Fisch MJ: Patient-clinician discordance
(PCD), distress, and quality of life (QOL) in cancer. Ann Behav Med 2013; 45(2 suppl): s100; Abst.
B-013. http://link.springer.com/content/pdf/10.1007%2Fs12160-013-9469-7.pdf
Protocol(s): E2Z02
NCI-Sponsored Groups Meetings Report 24 of 26
Summer 2013
Chandwani KD, Zhao F, Morrow GR, Shields TD, Minasian LM, Manola J, Fisch MJ: Lack of patient-
clinician concordance (LOC) across disease and treatment status in cancer. J Clin Oncol 2013; 31(15
suppl): Abst. E20520. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/e20520?sid=bf136000-a977-4d01-8455-129aec73eb1c
Protocol(s): E2Z02
NCCTG/Alliance
Barton D, Liu H, Tan A, Sloan J, Loprinzi C: Adiponectin: A novel biomarker for cancer-related
fatigue? Support Care Cancer 2013; 21(1 suppl): S197; Abst. MASCC-0560. http://link.springer.com/content/pdf/10.1007%2Fs00520-013-1798-3.pdf
Protocol(s): N07C2
Barton DL, Sloan JA, Novotny PJ, Fuloria J, Kottschade LA, Lyss AP, Jaslowski AJ, Mazurczak M,
Blair SC, Terstriep SA, Loprinzi CL: Does gabapentin prevent delayed chemotherapy-induced nausea
and vomiting (N/V)? Results of a randomized placebo controlled trial, NCCTG N08C3 (Alliance). J
Clin Oncol 2013; 31(15 suppl): Abst. 9513. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/9513?sid=f5fbb0b9-873c-412e-9597-3ddc4021a8c9
Protocol(s): N08C3
Barton DL, Sloan JA, Novotny PJ, Fuloria J, Kottschade LA, Lyss AP, Jaslowski AJ, Mazurczak MA,
Blair SC, Terstriep SA, Loprinzi CL: Can gabapentin improve control of delayed nausea and vomiting
(n/v)? A phase III placebo controlled trial, N08C3 (alliance). Support Care Cancer 2013; 21(1 suppl):
S197; Abst. MASCC-0562. http://link.springer.com/content/pdf/10.1007%2Fs00520-013-1798-3.pdf
Protocol(s): N08C3
Beutler AS, Kulkarni A, Kanwar R, Qin R, Cunningham JM, Therneau TM, Loprinzi CL: Sequencing
symptom control: Results from the Alliance N08C1 and N08CA genetics of chemotherapy neuropathy
trials. American Association for Cancer Research (AACR), Washington, DC, Apr 2013. Abst. LB-196. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=d4332bf8-005b-4cb2-a378-921ae4782081&cKey=52268d6b-7335-4aca-9338-653d6c27ffdb&mKey=%7b9B2D28E7-24A0-466F-A3C9-07C21F6E9BC9%7d
Protocol(s): N08C1, N08CA
Goetz M, Foster N, Meyers J, Steen P, Visscher D, Yoon H, Pillai R, Prow D, Reynolds C, Marchello
B, Mowat R, Mattar B, Erlichman C: Use of gene expression profiling to identify responsive patients
treated with carboplatin (Carb), paclitaxel (Pac), and everolimus as first-line treatment for cancer of
unknown primary (CUP): NCCTG N0871 (Alliance). J Clin Oncol 2013; 31(15 suppl): Abst. 2562. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/2562?sid=755fe5a5-3d26-446d-ae8a-09cce478bfdb
Protocol(s): N0871
Sarcoma/Bone and Soft Tissue Cancers
Alliance
Dickson MA, Mahoney MR, Marchello BT, Condy MM, Tap WD, Schwartz GK: Alliance A091102:
Phase II study of MLN8237 (alisertib) in advanced/metastatic sarcoma. J Clin Oncol 2013; 31(15
suppl): Abst. TPS10594. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/TPS10594?sid=8fb942c2-0fb6-4a7d-a297-f2aed046f675
Protocol(s): A091102
NCI-Sponsored Groups Meetings Report 25 of 26
Summer 2013
COG
Leary SE, Park JR, Reid JM, Ralya A, Baruchel S, Wu B, Ingle AM, Ahern CH, Weigel BJ, Blaney
SM: A phase I trial and pharmacokinetic study of trebananib (AMG386) in children with recurrent or
refractory solid tumors: A Children’s Oncology Group Phase 1 Consortium report. J Clin Oncol 2013;
31(15 suppl): Abst. 2538. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/2538?sid=81659e6b-89a5-4e39-af0f-34f90765b1f2
Protocol(s): ADVL1115 NCIC Clinical Trials Group Chow E, van der Linden Y, Roos D, Hartsell WF, Hoskin P, Wu JSY, Brundage M, Nabid A, Wilson
CF, Meyer RM, Chen BE, Wong R: A randomized trial of single versus multiple fractions (Fx) for re-
irradiation (RE-RT) of painful bone metastases (PBM): NCIC CTG SC.20. J Clin Oncol 2013; 31(15
suppl): Abst. 9502. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/9502?sid=8e5dc886-4a84-42c2-821e-7d908ec56efc
Other Participant(s) in the Trial: RTOG Protocol(s): NCIC CTG SC.20 (RTOG 0433) RTOG
Kane JM, Zhang Q, Klimowicz A, Magliocco A, George A, Simko J, DeLaney T, Kraybill W: High
Risk Soft Tissue Sarcoma Biomarker Expression Patterns and Outcome Following Neoadjuvant
Chemoradiation. Annals of Surgical Oncology 2013; 20(1 suppl): S28; Abst. 64. http://expo.jspargo.com/exhibitor/web/SSOAbstracts.pdf
Protocol(s): RTOG-95-14
NCI Abstracts
Abstracts with DCTD and/or DCP Investigators
Belani CP, Dahlberg SE, Rudin CM, Fleisher M, Chen HX, Takebe N, Ramalingam SS, Schiller JH:
Three-arm randomized phase II study of cisplatin and etoposide (CE) versus CE with either
vismodegib (V) or cixutumumab (Cx) for patients with extensive stage-small cell lung cancer (ES-
SCLC) (ECOG 1508). J Clin Oncol 2013; 31(15 suppl): Abst. 7508. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7508?sid=bea83189-fbee-4190-8a8e-952401aab275
Protocol(s): E1508
Chandwani KD, Zhao F, Morrow GR, Shields TD, Minasian LM, Manola J, Fisch MJ: Lack of patient-
clinician concordance (LOC) across disease and treatment status in cancer. J Clin Oncol 2013; 31(15
suppl): Abst. E20520. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/e20520?sid=bf136000-a977-4d01-8455-129aec73eb1c
Protocol(s): E2Z02
Goodman PJ, Thompson IM, Tangen CM, Parnes HL, Godley PA, Ford LG: Long-term survival of
subjects in the prostate cancer prevention trial. J Clin Oncol 2013; 31(6 suppl): Abst. 10. http://meeting.ascopubs.org/cgi/content/abstract/31/6_suppl/10?sid=0b66a628-dd0a-4bd5-bacb-09fcc1d016a0
Other Participant(s) in the Trial: CALGB/Alliance Protocol(s): SWOG-9217
NCI-Sponsored Groups Meetings Report 26 of 26
Summer 2013
Guertin KA, LaBarre J, Agler AH, Parker R, Arnold KB, Hartline J, Goodman PJ, Tangen C, Minasian
L, Lippman SM, Klein E, Cassano PA: The response to vitamin E supplementation. American Society
for Nutrition, Scientific Sessions & Annual Meeting at Experimental Biology, Boston, MA, Apr 2013. http://www.nutrition.org/education-and-professional-development/archived-content-from-past-meetings-and-professional-development-events/asn-at-eb-2013/
Protocol(s): S0000C
Massett H, Jaeckle KA, Dilts DM, Denicoff A, Souhan E, Hopkins JR, Mann BS: Rapid online
feedback to improve clinical trial accrual: CODEL anaplastic glioma (AG) (NCCTG/Alliance N0577)
as a model. J Clin Oncol 2013; 31(15 suppl): Abst. 1596. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/1596?sid=b80465e4-a247-4a22-a915-7a427bb84709
Protocol(s): N0577
Tang W, Guertin KA, Arnold KB, Crowley JJ, Hartline JA, Goodman PJ, Tangen CM, Minasian LM,
Lippman SM, Klein E, Cassano PA: A prudent diet attenuates lung function decline in cigarette
smokers. American Society for Nutrition, Scientific Sessions & Annual Meeting at Experimental
Biology, Boston, MA, Apr 2013. http://www.nutrition.org/education-and-professional-development/archived-content-from-past-meetings-and-professional-development-events/asn-at-eb-2013/
Protocol(s): S0000C
Disclaimer: References to abstracts included in this report are based on information provided to the EMMES Corporation
(CTEP/NCI contractor) by the individual Cooperative Groups and may not reflect all abstracts accepted or presented at the
indicated meetings. Inclusion of references under specific subheadings for Cooperative Group is based on information provided,
associated trials and information in references. References only appear under one disease heading and the Lead Cooperative
Group. Other participating Groups are listed separately. Abstracts that cannot be associated with DCTD (CTEP, CIP, RRP or
CDP) or DCP sponsored clinical trials or for which required information was not made available are excluded. Abstracts from
other relevant symposia in the same time period as the indicated meetings may be included upon agreement and provided the
required information is available. Links to online abstracts are provided if they were available at the time of publication, but there
is no guarantee that these links will remain active.